152 related articles for article (PubMed ID: 28178752)
1. Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma.
Kwon HJ; Choi JE; Kang SH; Son Y; Bae YK
Histopathology; 2017 Jun; 70(7):1155-1165. PubMed ID: 28178752
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
4. Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 - negative subtype.
Tanaka Y; Ohno T; Kadonaga T; Kidokoro Y; Wakahara M; Nosaka K; Sakabe T; Suzuki Y; Nakamura H; Umekita Y
Breast Cancer; 2021 Jul; 28(4):822-828. PubMed ID: 33481184
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer.
Park MH; Kwon SY; Choi JE; Gong G; Bae YK
Histopathology; 2020 Oct; 77(4):560-569. PubMed ID: 32333690
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Expressions of Senescence-Associated Secretory Phenotype and Its Association With Immune Microenvironments and Clinicopathological Factors in Invasive Breast Cancer.
Park MH; Choi JE; Kim JR; Bae YK
Pathol Oncol Res; 2021; 27():1609795. PubMed ID: 34267603
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor.
Chen WC; Lai YH; Chen HY; Guo HR; Su IJ; Chen HH
Histopathology; 2013 Aug; 63(2):225-33. PubMed ID: 23738752
[TBL] [Abstract][Full Text] [Related]
9. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
10. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
[TBL] [Abstract][Full Text] [Related]
15. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
[TBL] [Abstract][Full Text] [Related]
16. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
[TBL] [Abstract][Full Text] [Related]
19. RECK is not an independent prognostic marker for breast cancer.
Gomes LR; Fujita A; Mott JD; Soares FA; Labriola L; Sogayar MC
BMC Cancer; 2015 Oct; 15():660. PubMed ID: 26449734
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
